KV998054

KV998054 is an orally administered small molecule inhibitor of plasma kallikrein (KLKB1), developed by KalVista Pharmaceuticals. It acts as a KLKB1 (plasma kallikrein) inhibitor and has demonstrated the ability to prevent and reverse vascular endothelial growth factor (VEGF)-induced retinal edema in preclinical mouse models. The drug is being investigated for its potential use in treating diseases such as diabetic macular edema (DME) and other conditions where plasma kallikrein activity contributes to pathology, including hereditary angioedema (HAE). In animal studies, oral administration of KV998054 significantly reduced VEGF-stimulated retinal thickening, suggesting a possible therapeutic role in DME[1][2][3][6].